Treatment with MAP4K4 inhibitor GNE-495 reduced these tumor-promoting activities associated with MLK3 phosphorylation in vitro, and reduced tumor weight and MAP4K4 and MLK3 expression in vivo (78). The gene discussed is MAP4K4; the disease is neoplasm.